Drug Recall: Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Ma
Teva Pharmaceuticals USA, Inc · October 13, 2025
Reason for Recall
Subpotent drug; Clavulanate Potassium component
Product Description
Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
Distribution
Distributed in three (3) States: MS, OH, CA.
States Affected
CA, IN, MS, OH
Quantity Affected
4680 cartons
Source: FDA (openFDA Drug Enforcement)
Recall number: D-0151-2026
Status: ongoing
SafeCheck provides drug interaction information from FDA-approved product labeling (openFDA). This is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions.